Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients with Chronic Hepatitis C Infection

Journal of Pediatric Gastroenterology and Nutrition

Volumn 67, Issue 1, 2018, Pages 86-89

  Yakoot, Mostafa ^a   El Shabrawi, Mortada H ^b   Abdelgawad, Manal M ^c   Mahfouz, Aml A ^c   Helmy, Sherine ^d   Abdo, Alaa M ^c   El Khayat, Hisham R ^e  

^a Internal Medicine and Rheumatology   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c ALEXANDRIA UNIVERSITY   (Egypt)

^d Quality Control Department   (Egypt)

^e THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

Author keywords

adolescents; chronic hepatitis C; daclatasvir; efficacy; safety; sofosbuvir

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; DACLATASVIR; HEMOGLOBIN; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ANTIVIRAL THERAPY; ARTICLE; CHILD; CHRONIC HEPATITIS C; CLINICAL ARTICLE; COHORT ANALYSIS; COMBINATION DRUG THERAPY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTENTION TO TREAT ANALYSIS; KIDNEY FUNCTION; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PLATELET COUNT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; SCHOOL CHILD; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; VIRUS LOAD; CLINICAL TRIAL;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; PROSPECTIVE STUDIES; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; VIRAL LOAD;

EID: 85050119907     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000001968     Document Type: Article

References (8)

1. FDA News Release. FDA approves two hepatitis C drugs for pediatric patients. FDA Web site. Available at: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm551407.htm. Published April 7, 2017. (Accessed January 2, 2018).
2. AASLD-IDSA. HCV in children. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org/full-report/hcv-testing-and-linkage-care. (Accessed January 30, 2018).
3. Indolfi G, Hierro L, Dezsofi A, et al. Treatment of chronic hepatitis C virus infection in children. A position paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:505-15.
4. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL recommendations on treatment of Hepatitis C 2016. J Hepatol 2017;66:153-94.
5. Hill AM, Tahat L, Mohammed MK, et al. Bioequivalent pharmacokinetics for generic and originator hepatitis C direct acting antivirals: Poster Presented at AASLD - The Liver Meeting 2017, Abstract # 1078. Hepatology 2017;66 (S1):577A.
6. El-Shabrawi M, Abdo AM, El-Khayat H, et al. Shortened 8weeks course of dual sofosbuvir/daclatasvir therapy in adolescent patients, with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 2018;66: 425-42.
7. El-Sayed M, Hassany M, Asem N. A pilot study for safety and efficacy of 12 weeks sofosbuvir plus daclatasvir with or without ribavirin in Egyptian adolescents with chronic hepatitis C virus infection: Poster Presented at EASL-ILC 2017, Abstract # THU-412. J Hepatol 2017;66:S178Available at: http://www.journal-of-hepatology.eu/article/S0168-8278(17)30642-6/fulltext. (Accessed January 30, 2018).
8. Abdel Ghaffar T, El-Naghi S, Abdel-Gawad M, et al. The safety and efficacy of sofosbuvir & daclatasvir combined therapy for treatment of Egyptian children and adolescents with chronic hepatitis C (HCV)- genotype 4: interim results: Poster presented at AASLD - The Liver Meeting 2017, Abstract # LB-20. Hepatology 2017;66:1266A http://liverlearning.aasld.org/aasld/2017/thelivermeeting/201655/tawhida.yassin.abdel.ghaffar.the.safety.and.efficacy.of.sofosbuvir.%26.html (Accessed January 30, 2018).